Single Ascending and Multiple Ascending Dose Study of LCA-0061
Recruiting now · Phase 1 · Has a placebo group
Conditions studied: Atopic Disease, Peanut Allergies
In brief
This is a Phase 1combined single ascending dose (SAD)/multiple ascending dose (MAD) randomized, double-blind, placebo-controlled trial to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of single and multiple ascending subcutaneous doses of LCA-0061in participants with atopic conditions (SAD) and participants with peanut allergy (MAD).
Key facts
- Study ID
- NCT07701954
- Run by
- Lycia Therapeutics, Inc.
- People needed
- 72
- Starts
- 2026-06-26
- Expected to finish
- 2028-04-01
- Last updated by the study team
- 2026-07-14
Who can join
Age: 18 and older, up to 55. Sex: any. Healthy volunteers: not accepted.
Where it is running
- CAN001 — Mississauga, Ontario, Canada (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.